Category: NASDAQ:ESPR

Esperion’s Cholesterol Combo Pill Cuts Bad Cholesterol 35%

“Sometimes I think, gosh, it would be great if folks in the investment community could have that opportunity to sit in front of regulators and hear what they have to say,” says Tim Mayleben, Esperion’s chief executive.